25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Alx Oncology HoldingsĀ 
Buy, Hold or Sell?

Let's analyze Alx Oncology HoldingsĀ  together

I guess you are interested in Alx Oncology HoldingsĀ . Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Alx Oncology HoldingsĀ . At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Alx Oncology HoldingsĀ 

I send you an email if I find something interesting about Alx Oncology HoldingsĀ .

1. Quick Overview

1.1. Quick analysis of Alx Oncology HoldingsĀ  (30 sec.)










1.2. What can you expect buying and holding a share of Alx Oncology HoldingsĀ ? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
8.7%

What is your share worth?

Current worth
$2.59
Expected worth in 1 year
$1.99
How sure are you?
17.4%

+ What do you gain per year?

Total Gains per Share
$-0.61
Return On Investment
-36.5%

For what price can you sell your share?

Current Price per Share
$1.66
Expected price per share
$1.19 - $2.3
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Alx Oncology HoldingsĀ  (5 min.)




Live pricePrice per Share (EOD)
$1.66
Intrinsic Value Per Share
$-16.15 - $-18.53
Total Value Per Share
$-13.55 - $-15.93

2.2. Growth of Alx Oncology HoldingsĀ  (5 min.)




Is Alx Oncology HoldingsĀ  growing?

Current yearPrevious yearGrowGrow %
How rich?$136.8m$221.3m-$58.8m-36.2%

How much money is Alx Oncology HoldingsĀ  making?

Current yearPrevious yearGrowGrow %
Making money-$37.7m-$36.1m-$1.6m-4.5%
Net Profit Margin-458.4%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Alx Oncology HoldingsĀ  (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#318 / 950

Most Revenue
#544 / 950

Most Profit
#806 / 950

Most Efficient
#622 / 950
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Alx Oncology HoldingsĀ ?

Welcome investor! Alx Oncology HoldingsĀ 's management wants to use your money to grow the business. In return you get a share of Alx Oncology HoldingsĀ .

First you should know what it really means to hold a share of Alx Oncology HoldingsĀ . And how you can make/lose money.

Speculation

The Price per Share of Alx Oncology HoldingsĀ  is $1.66. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alx Oncology HoldingsĀ .
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alx Oncology HoldingsĀ , you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.59. Based on the TTM, the Book Value Change Per Share is $-0.15 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.56 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alx Oncology HoldingsĀ .

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.58-35.1%-0.72-43.2%-0.69-41.7%-0.50-30.4%-0.45-27.1%
Usd Book Value Change Per Share-0.43-25.7%-0.15-9.1%-0.56-33.8%0.137.8%0.116.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.43-25.7%-0.15-9.1%-0.56-33.8%0.137.8%0.116.8%
Usd Price Per Share1.82-8.47-7.03-22.21-19.32-
Price to Earnings Ratio-0.78--2.81--2.74--15.37--13.36-
Price-to-Total Gains Ratio-4.26--13.76--13.92--38.09--38.09-
Price to Book Ratio0.70-2.60-1.65-3.01-2.62-
Price-to-Total Gains Ratio-4.26--13.76--13.92--38.09--38.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.66
Number of shares602
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.150.13
Usd Total Gains Per Share-0.150.13
Gains per Quarter (602 shares)-91.1578.09
Gains per Year (602 shares)-364.61312.37
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-365-3750312302
20-729-7400625614
30-1094-11050937926
40-1458-1470012491238
50-1823-1835015611550
60-2188-2200018741862
70-2552-2565121862174
80-2917-2930124982486
90-3282-3295128112798
100-3646-3660131233110

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.023.00.00.0%0.023.00.00.0%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%4.016.00.020.0%4.016.03.017.4%4.016.03.017.4%
Dividend per Share0.00.04.00.0%1.00.011.08.3%2.00.018.010.0%2.00.021.08.7%2.00.021.08.7%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%4.016.00.020.0%4.016.03.017.4%4.016.03.017.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Alx Oncology HoldingsĀ  compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.427-0.151-65%-0.560+31%0.130-429%0.113-478%
Book Value Per Share--2.5943.081-16%4.196-38%4.262-39%3.706-30%
Current Ratio--4.8214.914-2%9.587-50%18.369-74%15.973-70%
Debt To Asset Ratio--0.2630.242+9%0.161+63%0.214+23%0.186+42%
Debt To Equity Ratio--0.3570.320+12%0.078+356%0.163+120%0.141+153%
Dividend Per Share----0%-0%0.000-100%0.000-100%
Eps---0.582-0.716+23%-0.692+19%-0.504-13%-0.451-23%
Free Cash Flow Per Share---0.484-0.617+27%-0.535+11%-0.405-16%-0.361-25%
Free Cash Flow To Equity Per Share---0.479-0.192-60%-0.489+2%0.137-450%0.117-510%
Gross Profit Margin--1.0001.0040%1.0000%1.0010%1.0010%
Intrinsic Value_10Y_max---18.526--------
Intrinsic Value_10Y_min---16.147--------
Intrinsic Value_1Y_max---2.080--------
Intrinsic Value_1Y_min---2.043--------
Intrinsic Value_3Y_max---6.079--------
Intrinsic Value_3Y_min---5.807--------
Intrinsic Value_5Y_max---9.873--------
Intrinsic Value_5Y_min---9.178--------
Market Cap87553546.000-10%95992442.000446865914.750-79%370520277.500-74%1171582480.300-92%1018767374.174-91%
Net Profit Margin----4.5840%-0%-795511.2030%-691749.2970%
Operating Margin----4.8410%-0%-755299.3490%-656782.4670%
Operating Ratio---4.841-100%-0%755299.516-100%656782.742-100%
Pb Ratio0.640-10%0.7022.605-73%1.653-58%3.014-77%2.621-73%
Pe Ratio-0.713+9%-0.782-2.812+260%-2.738+250%-15.368+1866%-13.363+1610%
Price Per Share1.660-10%1.8208.473-79%7.025-74%22.213-92%19.316-91%
Price To Free Cash Flow Ratio-0.858+9%-0.940-3.179+238%-3.557+278%-22.932+2339%-19.941+2021%
Price To Total Gains Ratio-3.890+9%-4.264-13.760+223%-13.922+226%-38.091+793%-38.091+793%
Quick Ratio--8.6908.882-2%17.054-49%22.032-61%19.159-55%
Return On Assets---0.165-0.176+6%-0.143-13%-0.136-18%-0.118-28%
Return On Equity---0.224-0.232+3%-0.070-69%-0.095-58%-0.083-63%
Total Gains Per Share---0.427-0.151-65%-0.560+31%0.130-429%0.113-478%
Usd Book Value--136807000.000162507750.000-16%221324000.000-38%224771300.000-39%195453304.348-30%
Usd Book Value Change Per Share---0.427-0.151-65%-0.560+31%0.130-429%0.113-478%
Usd Book Value Per Share--2.5943.081-16%4.196-38%4.262-39%3.706-30%
Usd Dividend Per Share----0%-0%0.000-100%0.000-100%
Usd Eps---0.582-0.716+23%-0.692+19%-0.504-13%-0.451-23%
Usd Free Cash Flow---25525000.000-32519750.000+27%-28217250.000+11%-21334850.000-16%-19064652.174-25%
Usd Free Cash Flow Per Share---0.484-0.617+27%-0.535+11%-0.405-16%-0.361-25%
Usd Free Cash Flow To Equity Per Share---0.479-0.192-60%-0.489+2%0.137-450%0.117-510%
Usd Market Cap87553546.000-10%95992442.000446865914.750-79%370520277.500-74%1171582480.300-92%1018767374.174-91%
Usd Price Per Share1.660-10%1.8208.473-79%7.025-74%22.213-92%19.316-91%
Usd Profit---30707000.000-37789750.000+23%-36102500.000+18%-26142800.000-15%-23231956.522-24%
Usd Revenue---620000.000-100%-0%243750.059-100%367739.182-100%
Usd Total Gains Per Share---0.427-0.151-65%-0.560+31%0.130-429%0.113-478%
 EOD+3 -5MRQTTM+12 -20YOY+15 -145Y+4 -3010Y+4 -30

3.3 Fundamental Score

Let's check the fundamental score of Alx Oncology HoldingsĀ  based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.713
Price to Book Ratio (EOD)Between0-10.640
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than18.690
Current Ratio (MRQ)Greater than14.821
Debt to Asset Ratio (MRQ)Less than10.263
Debt to Equity Ratio (MRQ)Less than10.357
Return on Equity (MRQ)Greater than0.15-0.224
Return on Assets (MRQ)Greater than0.05-0.165
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Alx Oncology HoldingsĀ  based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.480
Ma 20Greater thanMa 501.409
Ma 50Greater thanMa 1001.538
Ma 100Greater thanMa 2002.542
OpenGreater thanClose1.480
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Alx Oncology HoldingsĀ 

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-11-14 09:53:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitĀ Alx Oncology HoldingsĀ  earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Ā means thatĀ $0.00 for each $1Ā in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alx Oncology HoldingsĀ :

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-458.4%+458.4%
TTM-458.4%YOY--458.4%
TTM-458.4%5Y-79,551,120.3%+79,550,661.9%
5Y-79,551,120.3%10Y-69,174,929.7%-10,376,190.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--112.2%+112.2%
TTM-458.4%-221.4%-237.0%
YOY--210.0%+210.0%
5Y-79,551,120.3%-342.2%-79,550,778.1%
10Y-69,174,929.7%-464.5%-69,174,465.2%
4.3.1.2. Return on Assets

Shows howĀ efficientĀ Alx Oncology HoldingsĀ  is using its assets to generate profit.

  • Above 5% is considered healthyĀ but always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • -16.5% Return on Assets means thatĀ Alx Oncology HoldingsĀ  generatedĀ $-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alx Oncology HoldingsĀ :

  • The MRQ is -16.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -17.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.5%TTM-17.6%+1.1%
TTM-17.6%YOY-14.3%-3.3%
TTM-17.6%5Y-13.6%-4.0%
5Y-13.6%10Y-11.8%-1.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.5%-11.3%-5.2%
TTM-17.6%-11.7%-5.9%
YOY-14.3%-11.3%-3.0%
5Y-13.6%-12.7%-0.9%
10Y-11.8%-14.1%+2.3%
4.3.1.3. Return on Equity

Shows how efficient Alx Oncology HoldingsĀ  is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • -22.4% Return on Equity means Alx Oncology HoldingsĀ  generated $-0.22Ā for eachĀ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alx Oncology HoldingsĀ :

  • The MRQ is -22.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -23.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-22.4%TTM-23.2%+0.8%
TTM-23.2%YOY-7.0%-16.2%
TTM-23.2%5Y-9.5%-13.7%
5Y-9.5%10Y-8.3%-1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.4%-14.2%-8.2%
TTM-23.2%-15.9%-7.3%
YOY-7.0%-14.3%+7.3%
5Y-9.5%-18.5%+9.0%
10Y-8.3%-19.3%+11.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Alx Oncology HoldingsĀ .

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresĀ how efficient Alx Oncology HoldingsĀ  is operatingĀ .

  • Measures how much profit Alx Oncology HoldingsĀ  makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • An Operating Margin of 0.0%Ā means the company generated $0.00 Ā for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alx Oncology HoldingsĀ :

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-484.1%+484.1%
TTM-484.1%YOY--484.1%
TTM-484.1%5Y-75,529,934.9%+75,529,450.8%
5Y-75,529,934.9%10Y-65,678,246.7%-9,851,688.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--222.9%+222.9%
TTM-484.1%-310.7%-173.4%
YOY--223.5%+223.5%
5Y-75,529,934.9%-387.1%-75,529,547.8%
10Y-65,678,246.7%-498.5%-65,677,748.2%
4.3.2.2. Operating Ratio

Measures how efficient Alx Oncology HoldingsĀ  is keepingĀ operating costsĀ low.

  • Below 1 is considered healthy (always compare toĀ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alx Oncology HoldingsĀ :

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.841-4.841
TTM4.841YOY-+4.841
TTM4.8415Y755,299.516-755,294.675
5Y755,299.51610Y656,782.742+98,516.774
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.465-2.465
TTM4.8413.253+1.588
YOY-3.298-3.298
5Y755,299.5164.788+755,294.728
10Y656,782.7426.494+656,776.248
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Alx Oncology HoldingsĀ .

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Alx Oncology HoldingsĀ  is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toĀ Biotechnology industry mean).
  • A Current Ratio of 4.82Ā means the company has $4.82 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alx Oncology HoldingsĀ :

  • The MRQ is 4.821. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.914. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.821TTM4.914-0.094
TTM4.914YOY9.587-4.673
TTM4.9145Y18.369-13.454
5Y18.36910Y15.973+2.396
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8213.637+1.184
TTM4.9143.890+1.024
YOY9.5874.666+4.921
5Y18.3695.953+12.416
10Y15.9736.277+9.696
4.4.3.2. Quick Ratio

Measures if Alx Oncology HoldingsĀ  is able to pay off Short-term Debt but only usingĀ theĀ most liquid assets.

  • Above 1 is considered healthy butĀ always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • A Quick Ratio of 8.69Ā means the company can pay off $8.69 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alx Oncology HoldingsĀ :

  • The MRQ is 8.690. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.882. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.690TTM8.882-0.191
TTM8.882YOY17.054-8.173
TTM8.8825Y22.032-13.151
5Y22.03210Y19.159+2.874
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.6903.086+5.604
TTM8.8823.451+5.431
YOY17.0544.456+12.598
5Y22.0325.931+16.101
10Y19.1596.436+12.723
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Alx Oncology HoldingsĀ .

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Ā of Alx Oncology HoldingsĀ Ā assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareĀ Alx Oncology HoldingsĀ  to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.26Ā means that Alx Oncology HoldingsĀ  assets areĀ financed with 26.3% credit (debt) and the remaining percentage (100% - 26.3%)Ā is financed by its owners/shareholders.Ā 

Let's take a look of the Debt to Asset Ratio trends of Alx Oncology HoldingsĀ :

  • The MRQ is 0.263. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.242. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.263TTM0.242+0.022
TTM0.242YOY0.161+0.081
TTM0.2425Y0.214+0.028
5Y0.21410Y0.186+0.028
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2630.350-0.087
TTM0.2420.344-0.102
YOY0.1610.310-0.149
5Y0.2140.365-0.151
10Y0.1860.382-0.196
4.5.4.2. Debt to Equity Ratio

Measures ifĀ Alx Oncology HoldingsĀ  is able toĀ pay off its debts by usingĀ shareholders equity.

  • Below 2 is considered healthy butĀ always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • A Debt to Equity ratio of 35.7% means that company has $0.36 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alx Oncology HoldingsĀ :

  • The MRQ is 0.357. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.320. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.357TTM0.320+0.038
TTM0.320YOY0.078+0.241
TTM0.3205Y0.163+0.157
5Y0.16310Y0.141+0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3570.394-0.037
TTM0.3200.432-0.112
YOY0.0780.380-0.302
5Y0.1630.451-0.288
10Y0.1410.490-0.349
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresĀ how much money you payĀ for each share forĀ every $1 in earnings Alx Oncology HoldingsĀ  generates.

  • Above 15 is considered overpriced butĀ always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • A PE ratio of -0.78 means the investor is paying $-0.78Ā for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alx Oncology HoldingsĀ :

  • The EOD is -0.713. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.782. Based on the earnings, the company is expensive. -2
  • The TTM is -2.812. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.713MRQ-0.782+0.069
MRQ-0.782TTM-2.812+2.031
TTM-2.812YOY-2.738-0.074
TTM-2.8125Y-15.368+12.555
5Y-15.36810Y-13.363-2.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.713-2.303+1.590
MRQ-0.782-2.403+1.621
TTM-2.812-3.148+0.336
YOY-2.738-3.251+0.513
5Y-15.368-6.084-9.284
10Y-13.363-6.764-6.599
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alx Oncology HoldingsĀ :

  • The EOD is -0.858. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.940. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.179. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.858MRQ-0.940+0.083
MRQ-0.940TTM-3.179+2.238
TTM-3.179YOY-3.557+0.378
TTM-3.1795Y-22.932+19.753
5Y-22.93210Y-19.941-2.991
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.858-3.042+2.184
MRQ-0.940-3.234+2.294
TTM-3.179-3.719+0.540
YOY-3.557-4.557+1.000
5Y-22.932-8.332-14.600
10Y-19.941-9.276-10.665
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofĀ Alx Oncology HoldingsĀ  is to cheap or to expensiveĀ compared to its book value.

  • At or below 1 is considered healthyĀ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.70 means the investor is paying $0.70Ā for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alx Oncology HoldingsĀ :

  • The EOD is 0.640. Based on the equity, the company is cheap. +2
  • The MRQ is 0.702. Based on the equity, the company is cheap. +2
  • The TTM is 2.605. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.640MRQ0.702-0.062
MRQ0.702TTM2.605-1.903
TTM2.605YOY1.653+0.952
TTM2.6055Y3.014-0.409
5Y3.01410Y2.621+0.393
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6401.943-1.303
MRQ0.7022.051-1.349
TTM2.6052.356+0.249
YOY1.6532.454-0.801
5Y3.0143.714-0.700
10Y2.6214.378-1.757
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alx Oncology HoldingsĀ .

4.8.1. Institutions holding Alx Oncology HoldingsĀ 

Institutions are holding 108.644% of the shares of Alx Oncology HoldingsĀ .

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30venBio Partners LLC18.415825.2642969992500
2024-06-30FMR Inc14.83720.00378149962921843.884
2024-06-30Vivo Capital, LLC8.0122.3507422004800
2024-06-30Redmile Group, LLC7.66341.47164036451-290058-6.7042
2024-06-30Vestal Point Capital LP6.83481.6186360000099000037.931
2024-06-30BlackRock Inc5.10260.0004268761946605820.9789
2024-06-30MPM Oncology Impact Management LP4.14052.0436218086491239371.9286
2024-06-30Orbimed Advisors, LLC3.59670.22561894462-823508-30.2986
2024-06-30Vanguard Group Inc3.27930.0002172724816078410.2641
2024-06-30Paradigm Biocapital Advisors LP2.99140.3636157560515756050
2024-06-30Morgan Stanley - Brokerage Accounts2.55680.0003134671666044296.2359
2024-06-30Millennium Management LLC2.5160.0037132519612650062101.688
2024-06-30State Street Corp1.33950.000270554715168027.3856
2024-06-30Geode Capital Management, LLC1.32980.00047004069569215.8243
2024-06-30Marshall Wace Asset Management Ltd1.20690.0051635679514133422.9946
2024-06-30Renaissance Technologies Corp0.83190.004543820020410087.185
2024-06-30Privium Fund Management B.V.0.75370.57913969663969660
2024-06-30Kennedy Capital Management Inc0.58390.03963075293075290
2024-06-30Point72 Asset Management, L.P.0.57730.00483041003041000
2024-06-30Two Sigma Investments LLC0.55480.004292226226771346.4533
Total 87.124333.983245889783+7409877+16.1%

4.9.2. Funds holding Alx Oncology HoldingsĀ 

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-08-31Fidelity Small Cap Growth3.20350.05121689620-78260-4.4268
2024-09-30HBM Healthcare Investments AG Ord2.8440.1295150000000
2024-08-31Fidelity Series Small Cap Opps2.00450.04321057220130311.248
2024-09-30Vanguard Total Stock Mkt Idx Inv1.86680.000198458600
2024-09-30Fidelity Advisor Biotechnology I1.75230.089492423100
2024-10-31iShares Russell 2000 ETF1.64420.0018867199-1946-0.2239
2024-09-30Fidelity Select Biotechnology1.58410.030783550400
2024-08-31Fidelity Small Cap Growth K61.17830.0469621497-25029-3.8713
2024-08-31Fidelity Stock Selector Small Cap1.00160.031752830082001.5766
2024-09-30Vanguard Institutional Extnd Mkt Idx Tr0.76620.000740409600
2024-08-31Fidelity Small Cap Index0.64710.0029341318-4984-1.4392
2024-10-31iShares Russell 2000 Growth ETF0.56520.003629809400
2024-10-31State St Russell Sm/Mid CpĀ® Indx NL Cl C0.49110.0008259016-7000-2.6314
2024-10-31iShares Biotechnology ETF0.38240.0041201710-1206-0.5943
2024-09-30Fidelity Extended Market Index0.31850.000716800959273.6568
2024-09-30Vanguard Russell 2000 ETF0.28790.00221518421862013.9767
2024-10-31Schwab US Small-Cap ETFā„¢0.26020.00113721300
2024-09-30Vanguard VIF Small Co Gr0.23290.0143122837105637614.1686
2024-10-31State St Russell Sm CapĀ® Indx SL Cl I0.19610.001510343700
2024-08-31Fidelity Small Cap Stock0.18620.018698225-114900-53.912
Total 21.41310.474911293954-81910-0.7%

5.3. Insider Transactions

Insiders are holding 1.912% of the shares of Alx Oncology HoldingsĀ .

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-08-14Shelly PintoSELL5642.58
2024-08-14Sophia RandolphSELL13652.58
2024-07-11Jaume PonsSELL200007.9
2024-07-05Shelly PintoSELL18235.5
2024-07-01Shelly PintoSELL13735.82
2024-07-01Sophia RandolphSELL32735.82
2024-06-13Peter S GarciaBUY120008.53
2024-06-04Jaume PonsSELL200008.43
2024-05-13Sophia RandolphSELL1200015.94
2024-05-06Jaume PonsSELL2000015.92
2024-04-16Jaume PonsSELL5000014.2
2024-04-04Jaume PonsSELL2000011.15
2024-03-14Jason LettmannBUY440011.31
2024-01-04Shelly PintoSELL271713.6
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets185,715
Total Liabilities48,908
Total Stockholder Equity136,807
 As reported
Total Liabilities 48,908
Total Stockholder Equity+ 136,807
Total Assets = 185,715

Assets

Total Assets185,715
Total Current Assets155,895
Long-term Assets29,820
Total Current Assets
Cash And Cash Equivalents 16,102
Short-term Investments 132,472
Other Current Assets 7,321
Total Current Assets  (as reported)155,895
Total Current Assets  (calculated)155,895
+/-0
Long-term Assets
Property Plant Equipment 3,112
Long-term Assets Other 12,672
Long-term Assets  (as reported)29,820
Long-term Assets  (calculated)15,784
+/- 14,036

Liabilities & Shareholders' Equity

Total Current Liabilities32,340
Long-term Liabilities16,568
Total Stockholder Equity136,807
Total Current Liabilities
Accounts payable 7,891
Other Current Liabilities 24,449
Total Current Liabilities  (as reported)32,340
Total Current Liabilities  (calculated)32,340
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)16,568
Long-term Liabilities  (calculated)0
+/- 16,568
Total Stockholder Equity
Common Stock53
Retained Earnings -591,959
Accumulated Other Comprehensive Income 563
Other Stockholders Equity 728,150
Total Stockholder Equity (as reported)136,807
Total Stockholder Equity (calculated)136,807
+/-0
Other
Cash and Short Term Investments 148,574
Common Stock Shares Outstanding 52,694
Liabilities and Stockholders Equity 185,715
Net Debt -16,102
Net Working Capital 123,555



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
10,676
108,399
103,112
262,449
436,054
432,910
421,289
399,728
380,183
363,676
346,018
317,689
306,489
278,138
245,932
220,107
242,553
212,650
214,618
185,715
185,715214,618212,650242,553220,107245,932278,138306,489317,689346,018363,676380,183399,728421,289432,910436,054262,449103,112108,39910,676000
   > Total Current Assets 
0
0
0
9,809
107,413
100,664
262,404
434,219
432,327
412,277
388,963
367,019
321,525
316,847
290,808
270,969
232,536
219,561
199,071
188,659
167,864
168,712
155,895
155,895168,712167,864188,659199,071219,561232,536270,969290,808316,847321,525367,019388,963412,277432,327434,219262,404100,664107,4139,809000
       Cash And Cash Equivalents 
0
0
0
9,017
105,035
98,103
259,484
434,219
429,855
409,964
385,149
363,667
159,086
66,378
49,054
282,906
63,194
38,039
19,584
22,406
14,041
15,534
16,102
16,10215,53414,04122,40619,58438,03963,194282,90649,05466,378159,086363,667385,149409,964429,855434,219259,48498,103105,0359,017000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
157,510
246,988
235,855
217,385
164,750
174,797
170,425
160,330
143,396
141,189
132,472
132,472141,189143,396160,330170,425174,797164,750217,385235,855246,988157,510000000000000
       Net Receivables 
0
0
0
536
1,191
527
527
0
0
0
0
0
600
900
700
1,000
800
500
600
1,000
1,100
6,240
0
06,2401,1001,0006005008001,000700900600000005275271,191536000
       Other Current Assets 
0
0
0
256
1,187
1,393
2,393
1,773
2,472
2,313
3,814
3,352
4,929
3,481
5,899
4,762
4,592
6,725
9,062
4,923
9,327
5,749
7,321
7,3215,7499,3274,9239,0626,7254,5924,7625,8993,4814,9293,3523,8142,3132,4721,7732,3931,3931,187256000
   > Long-term Assets 
0
0
0
867
986
2,448
45
1,835
583
9,012
10,765
13,164
42,151
29,171
26,881
35,520
45,602
26,371
21,036
53,894
44,786
45,906
29,820
29,82045,90644,78653,89421,03626,37145,60235,52026,88129,17142,15113,16410,7659,0125831,835452,448986867000
       Property Plant Equipment 
0
0
0
860
757
37
45
52
47
167
562
3,472
6,967
8,235
8,639
9,813
9,551
9,066
9,808
10,841
10,245
10,704
3,112
3,11210,70410,24510,8419,8089,0669,5519,8138,6398,2356,9673,47256216747524537757860000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
25,109
10,860
8,217
16,699
28,220
11,647
6,435
35,411
27,049
29,475
0
029,47527,04935,4116,43511,64728,22016,6998,21710,86025,109000000000000
       Other Assets 
0
0
0
0
229
2,411
0
10
36
5,745
7,403
12,267
10,075
16,681
10,025
9,008
0
0
0
0
0
0
0
00000009,00810,02516,68110,07512,2677,4035,745361002,4112290000
> Total Liabilities 
0
0
0
10,952
9,282
12,467
10,433
436,054
14,426
16,275
14,556
17,134
20,080
29,699
30,726
43,025
37,750
33,240
51,355
52,841
48,455
55,301
48,908
48,90855,30148,45552,84151,35533,24037,75043,02530,72629,69920,08017,13414,55616,27514,426436,05410,43312,4679,28210,952000
   > Total Current Liabilities 
0
0
0
4,984
3,990
7,719
7,197
6,204
14,129
13,979
12,488
15,295
15,308
23,952
25,243
28,325
21,891
17,572
35,142
36,001
32,228
38,449
32,340
32,34038,44932,22836,00135,14217,57221,89128,32525,24323,95215,30815,29512,48813,97914,1296,2047,1977,7193,9904,984000
       Short-term Debt 
0
0
0
0
857
1,714
2,571
2,571
235
539
703
742
1,025
1,075
1,117
1,041
956
800
823
1,575
1,786
1,743
0
01,7431,7861,5758238009561,0411,1171,0751,0257427035392352,5712,5711,7148570000
       Short Long Term Debt 
0
0
0
0
857
1,714
2,571
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000002,5711,7148570000
       Accounts payable 
0
0
0
3,748
1,987
1,865
1,421
4
7,350
5,806
3,683
3,764
5,133
8,680
5,880
8,073
9,826
4,115
13,001
8,591
6,227
8,146
7,891
7,8918,1466,2278,59113,0014,1159,8268,0735,8808,6805,1333,7643,6835,8067,35041,4211,8651,9873,748000
       Other Current Liabilities 
0
0
0
1,236
349
301
240
6,200
103
205
102
257
9,150
14,197
18,246
19,211
11,109
13,457
22,141
25,835
24,215
28,560
24,449
24,44928,56024,21525,83522,14113,45711,10919,21118,24614,1979,1502571022051036,2002403013491,236000
   > Long-term Liabilities 
0
0
0
5,968
5,292
4,748
3,236
5
297
2,296
2,068
1,839
4,772
5,747
5,483
14,700
15,859
15,668
16,213
16,840
16,227
16,852
16,568
16,56816,85216,22716,84016,21315,66815,85914,7005,4835,7474,7721,8392,0682,29629753,2364,7485,2925,968000
       Long term Debt Total 
0
0
0
0
4,672
0
0
0
0
0
0
0
0
0
0
9,389
9,450
0
0
0
0
0
0
0000009,4509,38900000000004,6720000
       Other Liabilities 
0
0
0
0
620
820
47
5
0
0
0
1,839
1
5,747
0
53
0
1,309
0
0
0
0
0
000001,30905305,74711,8390005478206200000
       Deferred Long Term Liability 
0
0
0
0
200
2,411
0
0
0
0
0
9,548
0
0
0
0
0
0
0
0
0
0
0
000000000009,548000002,4112000000
> Total Stockholder Equity
0
0
0
-276
99,117
90,645
252,016
429,845
418,484
405,014
385,172
-201,985
343,596
316,319
286,963
-325,467
240,388
212,692
-440,800
189,712
164,195
159,317
136,807
136,807159,317164,195189,712-440,800212,692240,388-325,467286,963316,319343,596-201,985385,172405,014418,484429,845252,01690,64599,117-276000
   Common Stock
0
0
0
3
3
3
37
40
40
40
40
41
41
41
41
41
41
41
41
50
50
52
53
5352505041414141414141414040404037333000
   Retained Earnings Total Equity000000-355,651-325,467-294,758-259,438-226,518-201,985-173,547-148,981-132,707-118,5220000000
   Accumulated Other Comprehensive Income 
0
0
0
-1,449
-1,563
-92
-97
0
-30
0
0
0
-606
-1,256
-1,504
-845
-88
-312
-226
256
28
-73
563
563-7328256-226-312-88-845-1,504-1,256-606000-300-97-92-1,563-1,449000
   Capital Surplus 
0
0
0
0
2,289
0
0
548,327
551,151
553,955
558,679
564,993
570,679
576,972
583,184
589,735
596,086
0
0
0
0
0
0
000000596,086589,735583,184576,972570,679564,993558,679553,955551,151548,327002,2890000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
0
0
0
3,589
3,870
5,258
89,375
548,327
551,181
553,955
558,679
-41
570,679
576,972
583,184
804
596,086
602,773
185
675,678
685,970
720,590
728,150
728,150720,590685,970675,678185602,773596,086804583,184576,972570,679-41558,679553,955551,181548,32789,3755,2583,8703,589000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-836
Gross Profit-836-836
 
Operating Income (+$)
Gross Profit-836
Operating Expense-169,889
Operating Income-170,278-170,725
 
Operating Expense (+$)
Research Development141,795
Selling General Administrative28,483
Selling And Marketing Expenses836
Operating Expense169,889171,114
 
Net Interest Income (+$)
Interest Income10,649
Interest Expense-1,565
Other Finance Cost-0
Net Interest Income9,084
 
Pretax Income (+$)
Operating Income-170,278
Net Interest Income9,084
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-160,805-179,751
EBIT - interestExpense = -171,843
-160,805
-159,240
Interest Expense1,565
Earnings Before Interest and Taxes (EBIT)-170,278-159,240
Earnings Before Interest and Taxes (EBITDA)-169,442
 
After tax Income (+$)
Income Before Tax-160,805
Tax Provision-0
Net Income From Continuing Ops-160,805-160,805
Net Income-160,805
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses169,889
Total Other Income/Expenses Net9,473-9,084
 

Technical Analysis of Alx Oncology HoldingsĀ 
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alx Oncology HoldingsĀ . The general trend of Alx Oncology HoldingsĀ  is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alx Oncology HoldingsĀ 's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportĀ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceĀ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alx Oncology HoldingsĀ .

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.63 < 1.7696 < 2.3.

The bearish price targets are: 1.19.

Tweet this
Alx Oncology HoldingsĀ  Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows theĀ moving averageĀ of the selected period.

  • Moving averages are laggingĀ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alx Oncology HoldingsĀ . The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alx Oncology HoldingsĀ  Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theĀ momentumĀ of theĀ selected period based on two moving averages.

  • MACD is aĀ lagging momentumĀ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alx Oncology HoldingsĀ . The current macd is -0.02118462.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Alx Oncology HoldingsĀ  price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Alx Oncology HoldingsĀ . This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Alx Oncology HoldingsĀ  price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Alx Oncology HoldingsĀ  Daily Moving Average Convergence/Divergence (MACD) ChartAlx Oncology HoldingsĀ  Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alx Oncology HoldingsĀ . The current adx is 21.55.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Alx Oncology HoldingsĀ  shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Alx Oncology HoldingsĀ  Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsĀ the current trend.
  • ShowsĀ potential entry signals.
  • ShowsĀ Ā potential exit signals.
  • Can be used to placeĀ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alx Oncology HoldingsĀ . The current sar is 1.2214409.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Alx Oncology HoldingsĀ  Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumĀ indicator, meaning the signals are instant.
  • RangesĀ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alx Oncology HoldingsĀ . The current rsi is 59.48. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Alx Oncology HoldingsĀ  Daily Relative Strength Index (RSI) ChartAlx Oncology HoldingsĀ  Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesĀ a certain price to multiple prices ranging over time.

  • LeadingĀ momentumĀ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesĀ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alx Oncology HoldingsĀ . The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Alx Oncology HoldingsĀ  price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Alx Oncology HoldingsĀ  Daily Stochastic Oscillator ChartAlx Oncology HoldingsĀ  Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Ā the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alx Oncology HoldingsĀ . The current cci is 92.16.

Alx Oncology HoldingsĀ  Daily Commodity Channel Index (CCI) ChartAlx Oncology HoldingsĀ  Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alx Oncology HoldingsĀ . The current cmo is 38.83.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Alx Oncology HoldingsĀ  Daily Chande Momentum Oscillator (CMO) ChartAlx Oncology HoldingsĀ  Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Ā Shows the current price relative to the highest high over the last 14 days.
Ā 

  • Lagging momentum indicator
  • Ranging between 0 andĀ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alx Oncology HoldingsĀ . The current willr is -0.70731707.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Alx Oncology HoldingsĀ  Daily Williams %R ChartAlx Oncology HoldingsĀ  Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldĀ 

Score

Let's take a look at the Bollinger Bands of Alx Oncology HoldingsĀ .

Alx Oncology HoldingsĀ  Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alx Oncology HoldingsĀ . The current atr is 0.11690352.

Alx Oncology HoldingsĀ  Daily Average True Range (ATR) ChartAlx Oncology HoldingsĀ  Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Ā Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alx Oncology HoldingsĀ . The current obv is 11,870,205.

Alx Oncology HoldingsĀ  Daily On-Balance Volume (OBV) ChartAlx Oncology HoldingsĀ  Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alx Oncology HoldingsĀ . The current mfi is 36.34.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Alx Oncology HoldingsĀ  Daily Money Flow Index (MFI) ChartAlx Oncology HoldingsĀ  Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alx Oncology HoldingsĀ .

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-16STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-01STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-09-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-25BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-04MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-09MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-11-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Alx Oncology HoldingsĀ  Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alx Oncology HoldingsĀ  based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.480
Ma 20Greater thanMa 501.409
Ma 50Greater thanMa 1001.538
Ma 100Greater thanMa 2002.542
OpenGreater thanClose1.480
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Alx Oncology HoldingsĀ  with someone you think should read this too:
  • Are you bullish or bearish on Alx Oncology HoldingsĀ ? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alx Oncology HoldingsĀ ? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alx Oncology HoldingsĀ 

I send you an email if I find something interesting about Alx Oncology HoldingsĀ .


Comments

How you think about this?

Leave a comment

Stay informed about Alx Oncology HoldingsĀ .

Receive notifications about Alx Oncology HoldingsĀ  in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.